Abstract
Objectives: In the TRINOVA-1 study, weekly paclitaxel+trebananib significantly prolonged progression-free survival (PFS), the primary endpoint, over paclitaxel+placebo in women with recurrent epithelial ovarian cancer (EOC). Secondary objectives were prespecified analyses of objective and CA-125 responses. Post hoc analysis compared the relationship of CA-125 response vs Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
